Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the company will present data at two key scientific conferences this month on the latest in bladder cancer advancements using next-generation sequencing for multiple biomarker detection.

Predictive Biosciences will present two talks at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 6 – 10, 2013 in Washington, DC. The first presentation entitled, “Next-Gen deep amplicon sequencing of TP53 complements FGFR3 for the detection of bladder cancer-related mutations” will be given by Anthony P. Shuber, chief technology officer. The second presentation entitled, “Detection of bladder cancer-associated gene methylation using next-gen bisulfite sequencing” will be given by Cecilia Fernandez, director of research. Both presentations will be given on Sunday, April 7, 2013, from 1:00 p.m. - 5:00 p.m.

The company will also present at the 45th Annual Oak Ridge Conference, “Emerging Technologies for 21st Century Diagnostics” to be held April 18 – 19, 2013 in Baltimore, MD. Anthony P. Shuber will present on Friday, April 19, 3:10 – 3:25 p.m. EST in a session entitled “Biomarkers: Buyer Beware”. His talk will discuss the updates made to the company’s next-generation sequencing assay for bladder cancer, which includes the ability to analyze protein and DNA simultaneously on a next-generation sequencing platform.

“As the first company to introduce molecular diagnostic tests into routine clinical use using next-generation sequencing, we continue to leverage our proprietary technology based on the simultaneous detection of DNA and protein biomarkers. In addition to what we are presenting at these key scientific conferences, we are developing additional molecular tests applying our novel approaches to other cancers such as prostate cancer,” said Anthony P. Shuber.